Having demonstrated CK2 inhibitor can efficiently attenuate the phosphorylation of endogenous ARC and significantly increased the susceptibility of cancer cells to DOX in vitro, we further investigated CK2 inhibitor therapeutic potential in mouse xenograft model. The gene discussed is ARC; the disease is cancer.